Pfizer Q3 Report 2022

QUARTERLY FINANCIAL HIGHLIGHTS (Third-Quarter 2022 vs. Third-Quarter 2021)

Third-quarter 2022 revenues totaled $22.6 billion, a decrease of $1.4 billion, or 6%, compared to the prior-year quarter, reflecting an operational decline of $441 million, or 2%, as well as an unfavorable impact of foreign exchange of $957 million, or 4%. Excluding contributions from Paxlovid and Comirnaty, company revenues grew $213 million, or 2%, operationally.

Third-quarter 2022 operational decline was primarily driven by:

• Comirnaty outside the U.S., down 86% operationally, driven primarily by a previously announced
  amendment to the supply agreement with the European Commission (EC) whereby all doses scheduled for delivery in June through August 2022 would instead be delivered in the fourth quarter of 2022 and similar shifts in scheduled deliveries to other developed countries, as well as slower demand in emerging markets;
• Lower revenues for certain Comirnaty-related manufacturing activities performed on behalf of BioNTech SE (BioNTech), which decreased 96% operationally compared to the prior-year quarter;
• Xeljanz globally, down 14% operationally, driven primarily by decreased prescription volumes resulting
  from ongoing shifts in prescribing patterns related to Janus kinase (JAK) class label changes; and
• Sutent globally, down 43% operationally, primarily driven by lower volume demand in Europe following its loss of exclusivity in January 2022,